Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity

v3.23.2
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Treasury stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021   96,752,000        
Beginning balance at Dec. 31, 2021 $ 65,277 $ 10   $ 264,944 $ (199,325) $ (352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares (in shares)   23,000        
Exercise of stock options, net of vesting of restricted shares 16     16    
Release of restricted stock (in shares)   882,000        
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   96,000        
Issuance of common stock under the 2018 employee stock purchase plan 116     116    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   384,000        
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 1,125     1,125    
Stock-based compensation expense 1,264     1,264    
Cumulative translation adjustment (117)         (117)
Net income (loss) (31,988)       (31,988)  
Ending balance at Jun. 30, 2022 35,693 $ 10   267,465 (231,313) (469)
Ending balance (in shares) at Jun. 30, 2022   98,137,000        
Beginning balance (in shares) at Mar. 31, 2022   97,251,000        
Beginning balance at Mar. 31, 2022 51,990 $ 10   266,606 (214,242) (384)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Release of restricted stock (in shares)   790,000        
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   96,000        
Issuance of common stock under the 2018 employee stock purchase plan 116     116    
Stock-based compensation expense 743     743    
Cumulative translation adjustment (85)         (85)
Net income (loss) (17,071)       (17,071)  
Ending balance at Jun. 30, 2022 $ 35,693 $ 10   267,465 (231,313) (469)
Ending balance (in shares) at Jun. 30, 2022   98,137,000        
Beginning balance (in shares) at Dec. 31, 2022 103,153,337 103,153,000        
Beginning balance at Dec. 31, 2022 $ 24,881 $ 10 $ 0 275,562 (250,219) (472)
Beginning balance (in shares) at Dec. 31, 2022 0   0      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares (in shares)   95,000        
Exercise of stock options, net of vesting of restricted shares $ 58     58    
Release of restricted stock (in shares)   2,136,000        
Release of restricted stock 1 $ 1        
Issuance of restricted stock for earned bonus (in shares)   373,000        
Issuance of restricted stock for earned bonus 347     347    
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   93,000        
Issuance of common stock under the 2018 employee stock purchase plan 47     47    
Sales of common stock, net of issuance costs (in shares)   1,715,000        
Sales of common stock, net of issuance cost 995     995    
Stock-based compensation expense 2,828     2,828    
Cumulative translation adjustment 46         46
Treasury stock repurchase (in shares)     (507,000)      
Treasury stock repurchase (502)   $ (502)      
Net income (loss) (10,793)       (10,793)  
Ending balance at Jun. 30, 2023 $ 17,908 $ 11 $ (502) 279,837 (261,012) (426)
Ending balance (in shares) at Jun. 30, 2023 107,058,624 107,565,000        
Ending balance (in shares) at Jun. 30, 2023 (506,500)   (507,000)      
Beginning balance (in shares) at Mar. 31, 2023   104,470,000        
Beginning balance at Mar. 31, 2023 $ 21,901 $ 10 $ (475) 277,303 (254,488) (449)
Beginning balance (in shares) at Mar. 31, 2023     (462,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Release of restricted stock (in shares)   1,287,000        
Release of restricted stock 1 $ 1        
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   93,000        
Issuance of common stock under the 2018 employee stock purchase plan 47     47    
Sales of common stock, net of issuance costs (in shares)   1,715,000        
Sales of common stock, net of issuance cost 995 $ 0   995    
Stock-based compensation expense 1,492     1,492    
Cumulative translation adjustment 23         23
Treasury stock repurchase (in shares)     (45,000)      
Treasury stock repurchase (27)   $ (27)      
Net income (loss) (6,524)       (6,524)  
Ending balance at Jun. 30, 2023 $ 17,908 $ 11 $ (502) $ 279,837 $ (261,012) $ (426)
Ending balance (in shares) at Jun. 30, 2023 107,058,624 107,565,000        
Ending balance (in shares) at Jun. 30, 2023 (506,500)   (507,000)